Ata uhi

Bortezomib-induced neurotoxicity in human neurons is the consequence of nicotinamide adenine dinucleotide depletion

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Andrew R. Snavely (Author), Keungjung Heo (Author), Veselina Petrova (Author), Tammy Szu-Yu Ho (Author), Xuan Huang (Author), Crystal Hermawan (Author), Ruth Kagan (Author), Tao Deng (Author), Ilyas Singeç (Author), Long Chen (Author), Lee B. Barret (Author), Clifford J. Woolf (Author)
Hōputu:	Pukapuka
I whakaputaina:	The Company of Biologists, 2022-12-01T00:00:00Z.
Ngā marau:	article
Urunga tuihono:	Connect to this object online.
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite

The role of nicotinamide adenine dinucleotide salvage enzymes in cardioprotection
mā: Fazle Kibria, me ētahi atu.
I whakaputaina: (2024)

The Role of Nicotinamide Adenine Dinucleotide Phosphate Oxidases in Lung Architecture Remodeling
mā: Anantha Harijith, me ētahi atu.
I whakaputaina: (2017)

Erythrocyte nicotinamide adenine dinucleotide concentration is enhanced by systematic sports participation
mā: Barbara Pospieszna, me ētahi atu.
I whakaputaina: (2024)

Protective Effect of Nicotinamide Adenine Dinucleotide Phosphate on Renal Ischemia-Reperfusion Injury
mā: Xiao-fen Weng, me ētahi atu.
I whakaputaina: (2018)

Neuromeric Distribution of Nicotinamide Adenine Dinucleotide Phosphate-Diaphorase Activity in the Adult Lamprey Brain
mā: Manuel A. Pombal, me ētahi atu.
I whakaputaina: (2022)

Roles of Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidase in Angiogenesis: Isoform-Specific Effects
mā: Haibo Wang, me ētahi atu.
I whakaputaina: (2017)

Insight Into Nicotinamide Adenine Dinucleotide Homeostasis as a Targetable Metabolic Pathway in Colorectal Cancer
mā: Giorgia Colombo, me ētahi atu.
I whakaputaina: (2021)

Progress in research on mechanism of nicotinamide adenine dinucleotide and its precursors against aging-related diseases
mā: Shixiong ZHENG, me ētahi atu.
I whakaputaina: (2023)

Implication of Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidase and Its Inhibitors in Alzheimer's Disease Murine Models
mā: Leticia Guadalupe Fragoso-Morales, me ētahi atu.
I whakaputaina: (2021)

Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathways
mā: Chakrabarti G, me ētahi atu.
I whakaputaina: (2015)

Ex Vivo Lung Perfusion with β-Nicotinamide Adenine Dinucleotide (NAD<sup>+</sup>) Improves Ischemic Lung Function
mā: Jonas Peter Ehrsam, me ētahi atu.
I whakaputaina: (2022)

Rationale for Nicotinamide Adenine Dinucleotide (NAD+) Metabolome Disruption as a Pathogenic Mechanism of Post-Acute COVID-19 Syndrome
mā: Tabitha Block, me ētahi atu.
I whakaputaina: (2022)

Five Constituents in Psoralea corylifolia L. Attenuate Palmitic Acid-Induced Hepatocyte Injury via Inhibiting the Protein Kinase C-α/Nicotinamide-Adenine Dinucleotide Phosphate Oxidase Pathway
mā: Lishan Zhou, me ētahi atu.
I whakaputaina: (2020)

The Effectiveness of Four Nicotinamide Adenine Dinucleotide (NAD<sup>+</sup>) Precursors in Alleviating the High-Glucose-Induced Damage to Hepatocytes in <i>Megalobrama amblycephala</i>: Evidence in NAD<sup>+</sup> Homeostasis, Sirt1/3 Activation, Redox Defense, Inflammatory Response, Apoptosis, and Glucose Metabolism
mā: Yanzou Dong, me ētahi atu.
I whakaputaina: (2024)

Potential Neurotoxic Effects of Glioblastoma-Derived Exosomes in Primary Cultures of Cerebellar Neurons via Oxidant Stress and Glutathione Depletion
mā: Sidika Genc, me ētahi atu.
I whakaputaina: (2022)

Nicotinamide riboside kinases display redundancy in mediating nicotinamide mononucleotide and nicotinamide riboside metabolism in skeletal muscle cells
mā: Rachel S. Fletcher, me ētahi atu.
I whakaputaina: (2017)

Development and characterization of liposomal formulation of bortezomib
mā: Anil K. Deshantri, me ētahi atu.
I whakaputaina: (2019)

Response of Bortezomib Chemotherapy in Hepatic Amyloidosis
mā: Syed M. Hasan MD, me ētahi atu.
I whakaputaina: (2018)

Dinucleotide (CA)n tandem repeats on the human X-chromosome and the history of the Mediterranean populations
mā: Josep Santamaría, me ētahi atu.
I whakaputaina: (2018)

Estrogen receptor alpha dinucleotide repeat polymorphism in Japanese patients with autoimmune thyroid diseases
mā: Tozaki Teruaki, me ētahi atu.
I whakaputaina: (2000)

Successful treatment of mucous membrane pemphigoid with bortezomib
mā: Lina Saeed, BS, me ētahi atu.
I whakaputaina: (2018)

Bortezomib in Anti-Cancer Activity: A Potential Drug
mā: Rajagopal Appavu, me ētahi atu.
I whakaputaina: (2016)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
mā: Joseph Han, me ētahi atu.
I whakaputaina: (2023)

Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
mā: Pawel Robak, me ētahi atu.
I whakaputaina: (2019)

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
mā: Vallumsetla N, me ētahi atu.
I whakaputaina: (2015)

Polymeric Nanoparticles and Their Novel Modifications for Targeted Delivery of Bortezomib
mā: Saeideh Allahyari, me ētahi atu.
I whakaputaina: (2020)

Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide
mā: Mitsutoshi Satoh, me ētahi atu.
I whakaputaina: (2011)

Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia
mā: Park So-Yeon, me ētahi atu.
I whakaputaina: (2008)

Adenine: an important drug scaffold for the design of antiviral agents
mā: Changyuan Wang, me ētahi atu.
I whakaputaina: (2015)

Skin lesions caused by bortezomib targeted therapy of multiple myeloma
mā: Michał Sobjanek, me ētahi atu.
I whakaputaina: (2016)

Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats
mā: Shota Yamamoto, me ētahi atu.
I whakaputaina: (2015)

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
mā: Chen W, me ētahi atu.
I whakaputaina: (2016)

Guillain-Barré syndrome of a patient under bortezomib treatment
mā: María Mar Herráez-Albendea, me ētahi atu.
I whakaputaina: (2020)

Optimized Liposomal Delivery of Bortezomib for Advancing Treatment of Multiple Myeloma
mā: Chi Zhang, me ētahi atu.
I whakaputaina: (2023)

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib
mā: Paweł Robak, me ētahi atu.
I whakaputaina: (2020)

Lack of association between estrogen receptor β dinucleotide repeat polymorphism and autoimmune thyroid diseases in Japanese patients
mā: Tomita Motowo, me ētahi atu.
I whakaputaina: (2001)

Hidden Pool of Cardiac Adenine Nucleotides That Controls Adenosine Production
mā: Magdalena A. Zabielska-Kaczorowska, me ētahi atu.
I whakaputaina: (2023)

Macrophage Trafficking as Key Mediator of Adenine-Induced Kidney Injury
mā: Matheus Correa-Costa, me ētahi atu.
I whakaputaina: (2014)

Neurotoxicity New Advances
I whakaputaina: (2022)

Effects of nicotinamide on follicular development and the quality of oocytes
mā: Ziyu Guo, me ētahi atu.
I whakaputaina: (2022)